IRCT20150822023705N16尚未招募2 期
Investigating the effectiveness of adding famotidine and vitamin B6 to standard drug treatment in reducing negative symptoms in patients with schizophrenia disorder: a clinical trial with a control group
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- All
入选标准
- •Schizophrenia Disorder diagnoses with negative symptoms according to Diagnostic and Statistical Manual of Mental Disorders fifth edition by a psychiatrist
- •under treatment with aripiprazole
排除标准
- •Disagreement to participate in the study
研究者
相似试验
招募中
3 期
The effect of famotidine on reducing the side effects of prostate cancer radiotherapyIRCT20231121060132N1Kermanshah University of Medical Sciences50
进行中（未招募）
不适用
A trial, in which subjects with type 2 diabetes, who qualify for treatment intensification, are given insulin degludec and, additionally, either liraglutide or insulin aspart, both in combination with metformin, with the largest meal. The purpose is to compare efficacy and safety of these two treatments.EUCTR2011-001493-25-ATovo Nordisk A/S420
进行中（未招募）
不适用
A trial, in which subjects with type 2 diabetes, who qualify for treatment intensification, are given insulin degludec and, additionally, either liraglutide or insulin aspart, both in combination with metformin, with the largest meal. The purpose is to compare efficacy and safety of these two treatments.Type 2 diabetesMedDRA version: 14.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-001493-25-DEovo Nordisk A/S420
进行中（未招募）
不适用
A trial, in which subjects with type 2 diabetes, who qualify for treatment intensification, are given insulin degludec and, additionally, either liraglutide or insulin aspart, both in combination with metformin, with the largest meal. The purpose is to compare efficacy and safety of these two treatments.Diabetes tipo 2MedDRA version: 13.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-001493-25-ESovo Nordisk A/S420
进行中（未招募）
不适用
A trial, in which subjects with type 2 diabetes, who qualify for treatment intensification, are given insulin degludec and, additionally, either liraglutide or insulin aspart, both in combination with metformin, with the largest meal. The purpose is to compare efficacy and safety of these two treatments.EUCTR2011-001493-25-DKovo Nordisk A/S420